Interim results for the six months ended 30 Jun 25

AI SummaryClose X

Shield Therapeutics plc reported interim results for the six months ended June 30, 2025, with total revenues increasing 1.8x to $21.4 million compared to H1 2024. ACCRUFeR® revenue also grew 1.8x to $19.2 million. The company sold approximately 84,000 ACCRUFeR® prescriptions, with the average net selling price increasing by approximately 1.4x to $214. The Group's loss significantly narrowed to $9.5 million, compared to a $15.5 million loss in H1 2024. Cash and cash equivalents stood at $10.8 million, up from $6.5 million at the end of 2024, including $10.0 million from equity financing. Milestone payments of approximately $335,000 and $552,000 were received from VITAL-NET in Japan and Norgine BV in Europe, respectively. The company reaffirms its guidance to turn cash flow positive by the end of 2025.

Disclaimer*

UK 100

Latest directors dealings